Startups
Immunethep is a biotech startup company (spin-off from the University of Porto) that is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections.
The first product, PNV1 - Paragon Novel Vaccine, is a preventive strategy that will confer a robust protection against the main life threatening bacterial infections, including multi-resistant strains. PNV1 will be the first vaccine able to prevent multi-bacterial infections from all its serotypes from the womb until elderhood.
The first product, PNV1 - Paragon Novel Vaccine, is a preventive strategy that will confer a robust protection against the main life threatening bacterial infections, including multi-resistant strains. PNV1 will be the first vaccine able to prevent multi-bacterial infections from all its serotypes from the womb until elderhood.
Overview
Location
Portugal, Cantanhede
Employees
11-50
Founded date
2014
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Portugal Ventures | portugalventures.pt | |
| Sep 6, 2025 | CARB-X | carb-x.org |
Reviews 0
FAQ about IMMUNETHEP
When was IMMUNETHEP founded?
IMMUNETHEP was founded in 2014.
Who has invested in IMMUNETHEP?
Parsers VC lists 3 investors of IMMUNETHEP, among them CARB-X and Portugal Ventures.
Is IMMUNETHEP still active?
Yes, IMMUNETHEP is active; its latest activity on Parsers VC dates from Sep 6, 2025.